Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Semaglutide the original ~14.9% average body-weight reduction at 52 weeks Targets GLP-1 (one pathway) Weekly injection Best for: first-timers, or anyone sensitive to side effects Tirzepatide the upgrade ~22.1% average body-weight reduction at 52 weeks Targets GLP-1 + GIP (two pathways) Weekly injection Best for: plateaued on semaglutide, or want stronger results Retatrutide the newest ~25.9% average body-weight reduction at 52 weeks Targets GLP-1 + GIP + glucagon (three pathways) Weekly injection Best for: want the newest science, comfortable with a compounded option Semaglutide: the original Semaglutide is a GLP-1 receptor agonist
Early Phase 2 clinical data, including results published in the New England Journal of Medicine in 2023, has shown considerable promise, with participants achieving substantial reductions in body weight
A cotton ball or gauze should be used to press on it
Weight regain is common after the discontinuation of these medications
Demand has significantly outstripped supply, with Novo Nordisk even limiting new prescriptions in the US due to manufacturing constraints
